Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Odyssey Therapeutics
Biotech
Odyssey abandons IPO plans as 'not in best interests of company'
Odyssey Therapeutics has bailed on its long-awaited public listing in further evidence that the IPO window remains firmly shut for now.
James Waldron
Jun 10, 2025 7:25am
Odyssey, Sionna join band of biotechs braving the IPO waters
Jan 21, 2025 5:27am
Lonza lands new CEO—Chutes & Ladders
Apr 5, 2024 8:30am
Odyssey raises epic $101M to push programs off to clinical sea
Dec 5, 2023 11:01am
Lilly picks new head of diabetes, obesity unit—Chutes & Ladders
Oct 6, 2023 9:30am
Glick's Odyssey raises $168M to gear up for clinic
Oct 13, 2022 6:30am
